Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Morini, Monica ^a,b   Astigiano, Simonetta ^c   Gitton, Yorick ^d   Emionite, Laura ^c   Mirisola, Valentina ^c   Levi, Giovanni ^d   Barbieri, Ottavia ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; DISTAL LESS HOMEOBOX PROTEINS; DISTAL-LESS HOMEOBOX PROTEINS; DLX5 PROTEIN, HUMAN; DLX6 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DLX2 GENE; DLX5 GENE; DLX6 GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROGNOSIS; TUMOR GENE; ANIMAL; BONE TUMOR; BREAST TUMOR; CANCER INVASION; CELL MOTION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MORTALITY; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; ENDOTHELIN-1; FEMALE; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649326975     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-649     Document Type: Article

References (33)

1. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007, 26:6766-6776. 10.1038/sj.onc.1210760, 17934484.
2. Samuel S, Naora H. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. European Journal of Cancer 2005, 41:2428-2437. 10.1016/j.ejca.2005.08.014, 16199152.
3. Beverdam A, Merlo GR, Paleari L, Mantero S, Genova F, Barbieri O, Janvier P, Levi G. Jaw transformation with gain of symmetry after Dlx5/Dlx6 inactivation: mirror of the past?. Genesis 2002, 34:221-227. 10.1002/gene.10156, 12434331.
4. Perera M, Merlo GR, Verardo S, Paleari L, Corte G, Levi G. Defective neuronogenesis in the absence of Dlx5. Mol Cell Neurosci 2004, 25:153-161. 10.1016/j.mcn.2003.10.004, 14962748.
5. Merlo GR, Zerega B, Paleari L, Trombino S, Mantero S, Levi G. Multiple functions of Dlx genes. Int J Dev Biol 2000, 44:619-626.
6. Samee N, de Vernejoul MC, Levi G. Role of DLX regulatory proteins in osteogenesis and chondrogenesis. Crit Rev Eukaryot Gene Expr 2007, 17:173-186.
7. Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G, de Vernejoul MC. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol 2008, 173:773-780. 2527089, 18669617.
8. Ferrari N, Palmisano GL, Paleari L, Basso G, Mangioni M, Fidanza V, Albini A, Croce CM, Levi G, Brigati C. DLX genes as targets of ALL-1: DLX 2,3,4 down-regulation in t(4;11) acute lymphoblastic leukemias. J Leukoc Biol 2003, 74:302-305. 10.1189/jlb.1102581, 12885948.
9. Tan Y, Timakhov RA, Rao M, A AD, Xu J, Liu Z, Gao Q, Janwar SC, Di Cristofano A, Wiest DL, et al. A Novel Recurrent Chromosomal Inversion Implicates the Homeobox Gene Dlx5 in T-Cell Lymphoma from Lck-Akt2 Transgenic Mice. Cancer Research 2008, 68:1296-1302. 10.1158/0008-5472.CAN-07-3218, 18316591.
10. Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol 2007, 170:1594-1606. 10.2353/ajpath.2007.061025, 1854954, 17456765.
11. Stevenson HS, Fu SW, Pinzone JJ, Rheey J, Simmens SJ, PE B. BP1 transcriptionally activates bcl-2 and inhibits TNFalpha-induced cell death in MCF7 breast cancer cells. Breast Cancer Research 2007, 9:R60. 10.1186/bcr1766, 2242656, 17854498.
12. Pedersen N, Mortensen S, Sorensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS. Transcriptional Gene Expression Profiling of Small Cell Lung Cancer Cells. Cancer Research 2003, 63:1943-1953.
13. Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC, Risinger JI. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clinical Cancer Research 2005, 11:4056-4066. 10.1158/1078-0432.CCR-04-2001, 15930340.
14. Sato T, Kurihara Y, Asai R, Kawamura Y, Tonami K, Uchijima Y, Heude E, Ekker M, Levi G, Kurihara H. An endothelin-1 switch specifies maxillomandibular identity. Proceeding of the national Academy of Science USA 2008, 105:18806-18811.
15. Ozeki H, Kurihara Y, Tonami K, Watatani S, Kurihara H. Endothelin-1 regulates the dorsoventral branchial arch patterning in mice. Mech Dev 2004, 121:387-395. 10.1016/j.mod.2004.02.002, 15110048.
16. Charité J, McFadden DG, Merlo GR, Levi G, Clouthier DE, Yanagisaw M, Richardson JA, Olson EN. Role of Dlx6 in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer. Genes Dev 2001, 15:3039-3049. 10.1101/gad.931701, 312822, 11711438.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
18. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15. 10.1093/nar/gng015, 150247, 12582260.
19. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
20. Chelly J, Concordet J, Kaplan J, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989, 86:2617-2621. 10.1073/pnas.86.8.2617, 286968, 2495532.
21. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Biphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer research 1995, 55:3551-3557.
22. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastases of human breast carcinoma cell lines in nude mice. Cancer Research 1990, 50:717-721.
23. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceeding of the National Academy of Science USA 2003, 100:10954-10959.
24. Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Research and Treatment 2005, 90:241-247. 10.1007/s10549-004-4492-9, 15830137.
25. Kato T, Sato N, Takano A, Miyamoto M, Nishimura H, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clinical Cancer Research 2008, 14:2363-2370. 10.1158/1078-0432.CCR-07-1523, 18413826.
26. Zhou QP, Lee TN, Qiu X, Spencer V, de Melo J, Du G, Plews M, Fonseca M, Sun JM, Davie JR, Eisenstat DD. Identification of a direct Dlx homeodomain target in the developing mouse forebrain and retina by optimization of chromatin immunoprecipitation. Nucleic Acid Research 2004, 32:884-892.
27. Zerucha T, Stühmer T, Hatch G, Park BK, Long Q, Yu G, Gambarotta A, Schultz JR, Rubenstein JL, Ekker M. A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. Journal of neuroscience 2000, 20:709-721.
28. Ferrari N, Paleari L, Palmisano GL, Tammaro P, Levi G, Albini A, Brigati C. Induction of apoptosis by fenretinide in tumor cell lines correlates with DLX2, DLX3 and DLX4 gene expression. Oncology Report 2003, 10:973-977.
29. Grimshaw M. Endothelin in breast tumor cell invasion. Cancer Letters 2005, 222:129-138. 10.1016/j.canlet.2004.08.029, 15863261.
30. Dréau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clinical and Experimental Metastasis 2006, 23:41-53. 10.1007/s10585-006-9016-z, 16826430.
31. Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research 2005, 65:7320-7327. 10.1158/0008-5472.CAN-05-1403, 16103083.
32. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M, . Group. APS Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487. 10.1002/cncr.23864, 18785254, Group. APS.
33. Yamashita J, Ogawa M, Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 1995, 117:601-608. 10.1016/S0039-6060(95)80001-8, 7778023.